In Section A, contributors will receive different doses and schedules of oral ABBV-744 tablet to detect Protected dosing program. Additional individuals are going to be enrolled on the determined monotherapy dosign program. In Segment B, individuals will obtain oral ruxolitinib and ABBV-744 are going to be offered as "incorporate-on" therapy. https://abbv-744-preclinical-stud46790.bloggazzo.com/31218061/rumored-buzz-on-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers